Mutation of the DR5/TRAIL receptor 2 gene is infrequent in hepatocellular carcinoma
Journal
Cancer Letters
Journal Volume
181
Journal Issue
2
Pages
205-208
Date Issued
2002
Author(s)
Hsu H.-C.
Abstract
Chromosome 8p21-22 is a frequent site of loss of heterozygosity in many types of cancer, including hepatocellular carcinoma (HCC). Tumor necrosis factor-related apoptosis-inducing ligand-receptor 2 (TRAIL-R2/DR5), a member of tumor necrosis factor receptor family, is mapped to chromosome 8p21-22. Mutations of TRAIL-R2 have been detected in lung cancer, breast cancer, head and neck cancer, and non-Hodgkin's lymphoma. In this study, we analyzed the entire coding regions and all splicing sites of TRAIL-R2 in 40 HCCs and the death domain region in additional 60 HCCs. We could detect one point mutation in the death domain in only one HCC (1%). Our data suggest that somatic mutations of TRAIL-R2 gene do not play an important role in the carcinogenesis of HCC. ? 2002 Elsevier Science Ireland Ltd. All rights reserved.
SDGs
Other Subjects
tumor necrosis factor; article; breast cancer; carcinogenesis; chromosome 8p; chromosome map; controlled study; gene mutation; head and neck cancer; heterozygosity; Hodgkin disease; human; human tissue; liver cell carcinoma; lung cancer; point mutation; priority journal; promoter region; protein domain; RNA splicing; Carcinoma, Hepatocellular; Genes, Tumor Suppressor; Humans; Liver Neoplasms; Mutation; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor
Type
journal article